Open Access Open Access  Restricted Access Subscription Access
Total views : 15

A Review of the Aetiology, Characterisation, Diagnosis and Treatment of Alzheimer's Disease

Abstract


No Abstract.

Full Text:

 |  (PDF views: 0)

References


  • Alzheimer disease. Shaheen E Lakhan, Medscape Jul 26, 2017
  • Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016 Apr. 12 (4):459-509.
  • Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015 Dec. 86 (12):1299-306
  • Anderson, P. Early-Life Depression Boosts Alzheimer’s Risk. Medscape Medical News. July 24, 2017
  • Chiang GC, Insel PS, Tosun D, et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology. 2010 Nov 30. 75(22):1976-81
  • Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk Factors for ßAmyloid Deposition in Healthy Aging: Vascular and Genetic Effects. JAMA Neurol. 2013 Mar 18. 1-7.
  • Schrijvers JCM, Witteman EJG, Sijbrands, et al. Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study. Neurology. 2010;75:19821987.
  • Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010 Jul 6. 75(1):35-41
  • Lowry F. Late-life depression linked to increased risk for dementia. Medscape Medical News. May 7, 2013
  • Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of communitybased cohort studies. Br J Psychiatry. 2013 May. 202:329-35
  • Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009 May 28. 360(22):23029
  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May. 7(3):263-9. .
  • American Psychiatric Association. Neurocognitive Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013. 611-614.
  • McMillan CT, Avants B, Irwin DJ, Toledo JB, et al. Can MRI screen for CSF biomarkers in neurodegenerative disease?. Neurology. 2012 Dec 26
  • Brooks M. Functional Brain Imaging May Spot Alzheimer’s Early. Medscape Medical News. Aug 21 2013
  • Greig SL. Memantine ER/Donepezil: A Review in Alzheimer’s Disease. CNS Drugs. 2015 Nov. 29 (11):963-70
  • Small GW. Treating dementia and agitation. JAMA. 2014 Feb 19. 311(7):677-8
  • Wang YY, Zheng W, Ng CH, Ungvari GS, Wei W, Xiang YT. Meta-analysis of randomized, doubleblind, placebo-controlled trials of melatonin in Alzheimer’s disease. Int J Geriatr Psychiatry. 2016 Sep 19.
  • Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 1. 311(1):33-44.
  • Yaffe K, Boustani M. Benzodiazepines and risk of Alzheimer’s disease. BMJ. 2014 Sep 9. 349:g5312.

Refbacks

  • There are currently no refbacks.